PATENT CLAIM ANALYSIS

Application Number: 15902231
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "04400A"]

Abstract:
Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.

Claim (Index 3):
An antisense oligomer which is selected from a group consisting of (i) and (j) below, or a pharmaceutically acceptable salt or hydrate thereof:\n (i) an antisense oligomer which consists of a nucleotide sequence of SEQ ID NO: 1 or 2; and (j) an antisense oligomer which has a nucleotide sequence having at least 90% identity with a nucleotide sequence of SEQ ID NO: 1 or 2 and has an activity to cause skipping of the 51st exon in the human dystrophin gene.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 88.0
- Lexical Diversity: 1.27586
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15122435', '15759267', '15314535', '14368307', '15339069']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8626943722603226
- 35 USC 102 Novelty (BERT): 0.5935808263945812
- Combined Prediction Score: 0.8357830176737485
- Mean Citation Score: 498.759106
- Max Citation Score: 553.2
- Similarity Product: 444.3885073900223

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test